PMID- 35781675
OWN - NLM
STAT- MEDLINE
DCOM- 20220829
LR  - 20220930
IS  - 1535-1645 (Electronic)
IS  - 1523-3812 (Linking)
VI  - 24
IP  - 9
DP  - 2022 Sep
TI  - Managing Behavioral and Psychological Symptoms of Dementia (BPSD) in the Era of 
      Boxed Warnings.
PG  - 431-440
LID - 10.1007/s11920-022-01347-y [doi]
AB  - PURPOSE OF REVIEW: To provide a comprehensive overview on the evaluation and 
      management of behavioral and psychological symptoms of dementia (BPSD) using 
      evidence from literature. RECENT FINDINGS: Evidence indicates efficacy for some 
      non-pharmacological techniques including education of caregivers and cognitive 
      stimulation therapy and pharmacological agents like antidepressant and 
      antipsychotics for the management of BPSD. The use of antipsychotics has 
      generated controversy due to the recognition of their serious adverse effect 
      profile including the risk of cerebrovascular adverse events and death. BPSD is 
      associated with worsening of cognition and function among individuals with 
      dementia, greater caregiver burden, more frequent institutionalization, overall 
      poorer quality of life, and greater cost of caring for these individuals. Future 
      management strategies for BPSD should include the use of technology for the 
      provision of non-pharmacological interventions and the judicious use of 
      cannabinoids and interventional procedures like ECT for the management of 
      refractory symptoms.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Tampi, Rajesh R
AU  - Tampi RR
AD  - Department of Psychiatry, Creighton University School of Medicine, Omaha, NE, 
      USA. rajesh.tampi@gmail.com.
AD  - Department of Psychiatry &Behavioral Sciences, Cleveland Clinic Akron General, 
      Akron, OH, USA. rajesh.tampi@gmail.com.
AD  - Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, 
      Cleveland, OH, USA. rajesh.tampi@gmail.com.
AD  - Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA. 
      rajesh.tampi@gmail.com.
AD  - Department of Psychiatry, North East Medical University, Rootstown, OH, USA. 
      rajesh.tampi@gmail.com.
FAU - Bhattacharya, Gargi
AU  - Bhattacharya G
AD  - Department of Psychiatry &Behavioral Sciences, Cleveland Clinic Akron General, 
      Akron, OH, USA.
FAU - Marpuri, Padmapriya
AU  - Marpuri P
AD  - Frontier Psychiatry, Billings, MT, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220704
PL  - United States
TA  - Curr Psychiatry Rep
JT  - Current psychiatry reports
JID - 100888960
RN  - 0 (Antipsychotic Agents)
SB  - IM
MH  - *Antipsychotic Agents/adverse effects
MH  - Behavioral Symptoms/etiology/therapy
MH  - Caregivers/psychology
MH  - *Dementia/psychology
MH  - Drug Labeling
MH  - Humans
MH  - Quality of Life
OTO - NOTNLM
OT  - Behavioral and psychological symptoms of dementia (BPSD)
OT  - Cannabinoids
OT  - Electroconvulsive therapy (ECT)
OT  - Neuropsychiatric inventory (NPI)
OT  - Neuropsychiatric symptoms (NPS)
OT  - Non-pharmacological management
OT  - Pharmacological strategies
EDAT- 2022/07/06 06:00
MHDA- 2022/08/30 06:00
CRDT- 2022/07/05 09:22
PHST- 2022/06/08 00:00 [accepted]
PHST- 2022/07/06 06:00 [pubmed]
PHST- 2022/08/30 06:00 [medline]
PHST- 2022/07/05 09:22 [entrez]
AID - 10.1007/s11920-022-01347-y [pii]
AID - 10.1007/s11920-022-01347-y [doi]
PST - ppublish
SO  - Curr Psychiatry Rep. 2022 Sep;24(9):431-440. doi: 10.1007/s11920-022-01347-y. 
      Epub 2022 Jul 4.